Asian scientist working in laboratory
Applications & Insights

Laboratory developed tests

More relevant than ever – the need for laboratory developed tests grows

Today´s health management is hardly possible without laboratory developed tests (LDTs). The need for fast response time in disease outbreak situations and the lack of approved complete IVD workflows for many diseases make LDTs essential for patient care and health management.

QIAGEN – a leader in molecular diagnostics – provides solutions which enable your lab to set up and provide LDTs, fast, efficiently and effectively.

QIAsymphony machine
ccfDNA extraction. Perfected. Automated.

The use of cell-free DNA (ccfDNA) is transforming how we understand and manage clinical care. See how the QIAsymphony DSP Circulating DNA Kits can help you can improve your ccfDNA extraction protocols.

Loading samples

Workflows that work for you

We offer modules for your IVD workflows, automated sample prep,reaction setup, and real-time PCR. Our modular PCR workflows are compatible with your existing lab infrastructure. For labs that require an integrated workflow, we offer solutions that handle assays for a wild variety of samples and provide ultra-fast integrated PCR with true random access and an unprecedented streamlined workflow.

Transitioning to IVDR with QIAGEN

With QIAGEN, your lab can approach the transition to IVDR with confidence. We are committed to providing labs and healthcare professionals with the tests and products you need. Allowing patients to receive the answers they need.
Image from Biolab in Oman
QIAcuityDx

Redefine your lab developed tests

Digital PCR (dPCR) is a powerful technology for your laboratory developed tests (LDTs). It enables the absolute quantification of nucleic acid targets, and offers enhanced precision when compared to traditional PCR methods.

Disclaimers:

QIAcuity Digital PCR instruments are sold under license from Bio-Rad Laboratories, Inc. and exclude rights for use with pediatric applications

QIAcuityDx medical device is currently under development and will be available in 20 countries in H2 2024